# Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML

> **NCT05807932** · PHASE1,PHASE2 · RECRUITING · sponsor: **Heinrich-Heine University, Duesseldorf** · enrollment: 38 (estimated)

## Conditions studied

- Myelodysplastic Syndromes
- Secondary Acute Myeloid Leukemia
- Chronic Myelomonocytic Leukemia

## Interventions

- **DRUG:** Venetoclax
- **DRUG:** Amsacrine
- **DRUG:** Ara-C
- **DRUG:** Tacrolimus
- **DRUG:** Mycophenolate Mofetil

## Key facts

- **NCT ID:** NCT05807932
- **Lead sponsor:** Heinrich-Heine University, Duesseldorf
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-26
- **Primary completion:** 2026-01-31
- **Final completion:** 2028-01-30
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2024-05-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05807932

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05807932, "Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05807932. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*